{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-018522","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.318331+00:00","generated_at":"2026-06-19T17:56:09.495869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rezolute Q2 FY2023 net loss $13.6M; cash $146.7M; Phase 2 DME study initiated","bullets":["Net loss $13.6M for Q2 FY2023 ended Dec 31, 2022 vs $12.6M same period prior year.","Cash and cash equivalents $146.7M as of Dec 31, 2022.","R&D expenses $10.9M, G&A expenses $3.4M, both up on higher compensation and headcount.","Initiated Phase 2 proof-of-concept study for RZ402 in diabetic macular edema in Dec 2022.","Anticipates initiating global Phase 3 study for RZ358 in congenital hyperinsulinism mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-018522","json":"https://secwatch.observer/filing/0001104659-23-018522.json","markdown":"https://secwatch.observer/filing/0001104659-23-018522.md","text":"https://secwatch.observer/filing/0001104659-23-018522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/0001104659-23-018522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/tm236021d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T17:56:09.495869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9286af096fc6ccce71532d5bbfa9ba2fbca974c3","claim":"Rezolute, Inc. reported financial results for second quarter of fiscal 2023 ended December 31, 2022.","evidence_excerpt":"On February 10, 2023, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/0001104659-23-018522-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2023 ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}